Germline Screening of Cancer-Related Genes in Turkish Ovarian Cancer Patients

Esra Arslan Ates1,2, Ceren Alavanda3, Bilgen Bilge Geckinli3, Ahmet Ilter Guney3, Tuba Gunel2

1Department of Medical Genetics, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkiye
2Department of Molecular Biology and Genetics, Faculty of Sciences, Istanbul University, Istanbul, Turkiye
3Department of Medical Genetics, Faculty of Medicine, Marmara University, Istanbul, Turkiye

ORCID ID: E.A.A. 0000-0001-5552-8134; C.A. 0000-0002-7327-3849; B.B.G. 0000-0003-0317-5677; A.I.G. 0000-0002-1661-1282; T.G. 0000-0003-3514-5210


ABSTRACT

Objective: Ovarian cancer (OC) is one of the most fatal types of cancer and affects 1%-1.5% of women worldwide. The most common genes causing OC are the BRCA1 and BRCA2 genes. However, improvements in next-generation sequencing (NGS) technologies have allowed for screening of the various genes related to hereditary cancer syndromes. The aim of this study was to evaluate cancer-related gene variations among cases of ovarian cancer.

Materials and Methods: The study evaluated 63 cases that were referred to the Marmara University Pendik Training and Research Hospital Genetic Diseases Diagnostic Center between 2016-2021 with a diagnosis of OC for germline variations in 25 cancer-related genes using NGS. Large intragenic rearrangements of the BRCA1 and BRCA2 genes were screened using multiplex ligation-dependent probe amplification (MLPA).

Results: The study detected 12 distinct pathogenic variations in the BRCA1, BRCA2, BRIP1, and RAD50 genes in 13 OC cases. Four of the 13 cases involved copy number variations that included at least one exon of the BRCA1 gene.

Conclusion: This study detected pathogenic BRCA1 variations to be the leading cause of hereditary OC. The study showed just screening for BRCA1 to reveal the underlying hereditary defect in 76.9% of the cases, which seems higher compared to literature. More studies involving larger cohorts are necessary to figure out the exact frequency of BRCA1 variations in Turkish OC cases.

Keywords: Ovarian cancer, hereditary cancer syndromes, germline variation

INTRODUCTION

Ovarian cancer (OC) is one of the leading causes of cancer-related deaths worldwide among women. Every year, 240,000 women are diagnosed with OC, making it the seventh most common cancer globally. OC is frequently diagnosed in the later stages of the disease and is known as the most fatal gynecologic cancer with a five-year survival rate of less than 45%(1, 2).

Germline predisposition is one of the most significant risk factors for developing OC (3). A germline pathogenic variation is detected in cancer-related genes in approximately 23% of OC cases (4). BRCA1 and BRCA2 are the most common genes associated with hereditary ovarian cancer (5), with the worldwide population of women having a 1.8% lifetime risk for ovarian cancer. However, this risk increases up to 15%-45% for germline BRCA1 pathogenic variant carriers, and 10%-20% for BRCA2 pathogenic variant carriers (6). Among all hereditary OC patients, 15%-35% of pathogenic variations may be present in other tumor suppressor genes or oncogenes including mismatch repair (MMR) genes, TP53, ATM, CHEK2, PALB2, RAD50, and BRIP1 (5, 7). Identifying the underlying molecular defects in ovarian
cancer is an important approach for the medical management of patients and guidance regarding treatment options, and this study aimed to reveal the relationship between genetic variations and clinical outcomes.

MATERIALS AND METHODS

Patients Data
The study involved 63 patients who were referred to the medical genetics department with a diagnosis of OC between 2016-2021 and has obtained approval from the institutional review board with the protocol number 09.2020.751. Informed consent was obtained from all patients during the face-to-face interviews. The patients were evaluated in terms of age of diagnosis, clinical outcomes, and family history. CA-125 levels were obtained from their patient follow-up documents at the time of diagnosis.

Genetic Tests
DNA isolation from peripheral blood samples was performed using the QiAamp DNA Mini Kit (Qiagen, MD, USA). The BRCA1 and BRCA2 genes were amplified using the Multiplicom BRCA Master Dx (Agilent, CA, USA). Copy number variations (CNVs) in the BRCA1 and BRCA2 genes were screened using the SALSA multiplex ligation-dependent probe amplification (MLPA) Probemix P002 BRCA1 and P045 BRCA/CHEK2 kits (MRC Holland, Amsterdam, the Netherlands). The 25 genes associated with cancer predisposition (i.e., ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, FAM175A, MRE11A, NBN, PALB2, PIK3CA, RAD50, RAD51C, RAD51D, TP53, XRCC2, MLH1, MSH2, MSH6, PMS2, MUTYH, APC, PTEN, and STK11) were amplified using the Multiplicom BRCA Hereditary Cancer MASTR Plus kit (Agilent, CA, USA). Sequencing was performed on the Illumina NextSeq platform (Illumina Inc., San Diego, CA, USA). The obtained data have been analyzed in the analysis program Sophia DDM (Sophia Genetic Inc. Boston, MA 02116, USA). For the confirmation and segregation analyses of the detected variants, the target region was replicated with the designed primers and then sequenced with the ABI Prism 3500 Genetic Analyzer (Thermo Fisher Scientific, MA, USA) device using the Sanger sequencing method. Human reference genome Hg 19 was used for variant annotation and evaluated according to the American College of Medical Genetics and Genomics (ACMG) criteria (8).

Statistical Analysis
Data were evaluated via Microsoft Excel for Mac (version 15.33) application. Mean ages and percentage values were obtained using this software.

RESULTS

Between 2016-2021, 63 ovarian cancer cases were referred to the medical genetics department for genetic testing. These patients' ages ranged between 24-83, with the age at diagnosis ranging from 22-83 and a median age of diagnosis of 50 years. Two (3%) cases involved bilateral ovarian cancer, while three (4.7%) cases also had a history of breast cancer. Among the 63 cases, 48 (76%) reported at least one cancer case among family members, with 31 being first-degree, 13 being second-degree, and four being third-degree relatives. At least one family member had also been diagnosed with ovarian cancer in 17 (26.9%) of the cases, while 13 (20%) cases also had at least one family member who suffered from breast cancer.

Other cancer types such as gastrointestinal tract, lung, and endometrium cancers were reported for family members in 18 (28%) of the cases; these cases also showed no family history of ovarian or breast cancer. In 15 (23.8%) cases, no family history was found for any kind of cancer.

Firstly, the BRCA1/2 genes were evaluated for single nucleotide variations (SNVs) and CNVs, with a pathogenic variation related to hereditary breast/ovarian cancer being detected in 11 (17%) patients, 10 of the 11 variants were found in the BRCA1 gene and one of the 11 variant was found in the BRCA2 gene. In three cases, two missense mutations, one nonsense mutation, and two frameshift mutations in the BRCA1 gene were detected. In four cases, the MLPA revealed three distinct intragenic deletions and one duplication. No variations were detected in the related exons or adjacent sequences within at least 20 base pairs in the introns. A frameshift BRCA2 variation be detected in only one case.

Non-BRCA cases were screened for 25 breast cancer-causing genes. Among 52 cases, only two (2.8%) cases, pathogenic variations were detected in the BRIP1 and RAD50 genes. The BRIP1 c.139C>G (p.Pro47Ala) variation was detected in a 55 year-old OC patient who had multiple family members diagnosed with breast and/or ovarian cancer. The RAD50 c.2083C>T (p.Gln695*) variation causing a truncated protein was detected in a 28-year-old OC patient with no records in the ClinVar or Human Gene Mutation Database (HGMD). According to ACMG criteria, this variation is predicted to be deleterious. She had an aunt who died at the age of 60 from skin cancer, but no further data was available regarding her cancer histopathology or clinical outcome. The CNVs analyses of these 25 genes using the Sophia DDM CNV detection algorithm detected no copy number variations; however, the study was not able to screen CNVs using MLPA. This case was also reported in a previous study (9) evaluating hereditary cancer cases independent of cancer type.

Table 1 specifies all pathogenic variations and characteristics of the patients carrying pathogenic variations, Figure 1 presents the visualizations from the Integrative Genomics Viewer (IGV), and Figure 2 shows the data from the MLPA.

A positive family history was present in 11 of 13 (84%) cases involving a pathogenic variation, with four reported ovarian cancer diagnoses in a first-degree relative, three reported breast cancer cases in first- and second-degree relatives, and three cases reporting other types of cancers including gastrointestinal, lung, and endometrial cancers in more than two relatives.

In six cases, the study detected six variations in the BRCA1, BRCA2, PALB2, CHEK2, and CDH1 genes that were classified as “variant of uncertain significance” (VUS) according to the ACMG criteria (Table 2; Figure 3).
<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>Clinical Presentation</th>
<th>Family History</th>
<th>Gene (Transcript)</th>
<th>Variation</th>
<th>Coding Consequence</th>
<th>HGMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>Unilateral Ovarian Ca</td>
<td>-</td>
<td>BRCA1 (NM_007294)</td>
<td>c.181T&gt;G</td>
<td>Missense</td>
<td>CM940172-DM (Breast cancer)</td>
</tr>
<tr>
<td>34</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Pancreas Ca (Second degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>c.2019delA (p.Glu673Aspfs*28)</td>
<td>Frameshift</td>
<td>CD021407-DM (Ovarian cancer)</td>
</tr>
<tr>
<td>57</td>
<td>Unilateral Ovarian Ca</td>
<td>-</td>
<td>BRCA1 (NM_007294)</td>
<td>c.2800C&gt;T (p.Gln934*)</td>
<td>Nonsense</td>
<td>CM004607-DM (Ovarian cancer)</td>
</tr>
<tr>
<td>50</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Breast and Ovarian Ca (First and second degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>c.5074G&gt;C (p.Asp1692His)</td>
<td>Missense</td>
<td>CM129092-DM? (Breast cancer)</td>
</tr>
<tr>
<td>47</td>
<td>Bilateral Ovarian Ca + Breast Ca</td>
<td>+ Breast and Ovarian Ca (First degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>c.5266dupC (p.Gln1756Profs*74)</td>
<td>Frameshift</td>
<td>CI941841-DM (Breast cancer)</td>
</tr>
<tr>
<td>56</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Ovarian Ca (First degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>c.5266dupC (p.Gln1756Profs*74)</td>
<td>Frameshift</td>
<td>CI941841 (Breast cancer)</td>
</tr>
<tr>
<td>54</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Breast Ca (First degree relative) Thyroid ca (Second Degree Relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>Exon 3-8 dup</td>
<td>CNV</td>
<td>CN025048-DM (Breast and/or ovarian cancer)</td>
</tr>
<tr>
<td>42</td>
<td>Unilateral Ovarian Ca + Breast Ca</td>
<td>+ Breast Ca (First degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>EX 18-19 DEL</td>
<td>CNV</td>
<td>CG146559-DM (Breast cancer)</td>
</tr>
<tr>
<td>45</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Breast Ca (First degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>EX21-23 DEL</td>
<td>CNV</td>
<td>CG052603-DM (Breast and/or ovarian cancer)</td>
</tr>
<tr>
<td>40</td>
<td>Unilateral Ovarian Ca + Breast Ca</td>
<td>+ Endometrium Ca (First degree relative)</td>
<td>BRCA1 (NM_007294)</td>
<td>Exon 24 del</td>
<td>CNV</td>
<td>CG146555-DM (Ovarian cancer)</td>
</tr>
<tr>
<td>50</td>
<td>Unilateral Ovarian Ca + Breast Ca</td>
<td>+ Endometrium Ca (second degree relative)</td>
<td>BRCA2 (NM_000059)</td>
<td>c.6405_6409del (p. Asn2135Lysfs*3)</td>
<td>Frameshift</td>
<td>CD972084-DM (Breast cancer)</td>
</tr>
<tr>
<td>55</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Breast and Ovarian Ca (First Degree relative) Pancreas Ca (Second Degree Relative)</td>
<td>BRIP1 (NM_032043)</td>
<td>c.139C&gt;G (p.Pro47Ala)</td>
<td>Missense</td>
<td>CM014756-DM (Breast cancer)</td>
</tr>
<tr>
<td>28</td>
<td>Unilateral Ovarian Ca</td>
<td>+ Malign Melanoma (second degree relative)</td>
<td>RAD50 (NM_005732)</td>
<td>c.2083C&gt;T (p.Gln695*)</td>
<td>Nonsense</td>
<td>Novel</td>
</tr>
</tbody>
</table>
DISCUSSION

This study has investigated 63 ovarian cancer patients for germline variations among 25 cancer-related genes. A family history of ovarian cancer and certain other neoplasms including breast, colorectal, and endometrium cancers are also well-known risk factors for OC (10). The current study reported 49% of cases (n = 31) to have at least one first-degree relative with a history of cancer. This finding is consistent with a previous study which had reported as 40% in a large cohort (11). The current study also evaluated family history up to third-degree relations, which observed this ratio increase up to 76% (n = 48). Although family history was not an inclusion criterion for this study, this high rate is thought to be due to the tendency of clinicians to refer patients to genetics department when a family history of cancer is already present.

Figure 1. Integrative genomics viewer (IGV) visualizations of detected pathogenic variants.

a) BRCA1 heterozygous c.2019delA (p.Glu673Aspfs*28),
b) BRCA1 heterozygous c.2800C>T (p.Gln934*),
c) BRCA1 heterozygous c.5074G>C (p.Asp1692His),
d) BRCA1 heterozygous c.5266dupC (p.Gln1756Profs*74),
e) BRCA2 heterozygous c.6405_6409del (p.Asn2135Lysfs*3),
f) BRIP1 heterozygous c.139C>G (p.Pro47Ala),
g) RAD50 heterozygous c.2083C>T (p.Gln695*)

Figure 2. Multiplex Ligation-Dependent Probe Amplification (MLPA) data of copy number variants.
a) BRCA1 heterozygous exon 21-23 deletion,
b) BRCA1 heterozygous exon 18-19 deletion.
Table 2. The VUSs detected in the study.

<table>
<thead>
<tr>
<th>Age at diagnosis</th>
<th>Gene/ Transcript</th>
<th>Variation</th>
<th>Frequency in our Inhouse database</th>
<th>MAF (GnomAD)</th>
<th>Mutation Taster</th>
<th>DANN</th>
<th>GERP</th>
<th>ClinVar/ HGMD</th>
<th>dbSNP</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>PALB2 NM_024675</td>
<td>c.3306C&gt;G (p.Ser1102Arg)</td>
<td>0.00005</td>
<td>0.000007953 Polymorphism</td>
<td>0.7592</td>
<td>6.1399</td>
<td>VUS/DM? (Breast cancer)</td>
<td>rs515726112</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>PALB2 NM_024675</td>
<td>c.3508C&gt;A p.His1170Asn</td>
<td>0.00005</td>
<td>- Polymorphism</td>
<td>0.9857</td>
<td>5.9</td>
<td>VUS/-</td>
<td>rs200283306</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>CDH1 NM_004360</td>
<td>c.2602C&gt;T p.(Arg868Cys)</td>
<td>0.00006</td>
<td>- Disease Causing</td>
<td>0.9984</td>
<td>6.17</td>
<td>VUS/-</td>
<td>rs864622630</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>CHEK2 NM_001005735</td>
<td>c.157T&gt;A (p.Ser53Thr)</td>
<td>0.00005</td>
<td>0.00004773 Disease Causing</td>
<td>0.9981</td>
<td>5.42</td>
<td>VUS/-</td>
<td>rs371657037</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>BRCA1 NM_007294</td>
<td>c.401_403dupCCA (p.Ala134_Lys135insThr)</td>
<td>0.00003</td>
<td>- Polymorphism</td>
<td>0.532</td>
<td>VUS/-</td>
<td>rs1555596338</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>BRCA2 NM_000059</td>
<td>c.8416T&gt;C (p.Ser2806Pro)</td>
<td>0.00003</td>
<td>- Disease Causing</td>
<td>0.9989</td>
<td>5.19</td>
<td>VUS/DM (Prostate cancer)</td>
<td>rs1280487930</td>
<td></td>
</tr>
</tbody>
</table>


Figure 3. Integrative genomics viewer (IGV) visualizations of detected VUS.

a) PALB2 heterozygous c.3306C>G (p.Ser1102Arg),
b) CDH1 heterozygous c.2602C>T (p.Arg868Cys),
c) CHEK2 heterozygous c.157T>A (p.Ser53Thr),
d) PALB2 heterozygous c.3508C>A (p.His1170Asn),
e) BRCA1 heterozygous c.401_403dupCCA (p.Ala134_Lys135insThr),
f) BRCA2 heterozygous c.8416T>C (p.Ser2806Pro).
Among the 48 family-history positive patients, 30 (62.5%) reported breast and/or ovarian cancer in other family members, which suggests that hereditary breast and ovarian cancer syndrome (HBOCS) is related to the BRCA1 and BRCA2 genes. Germline pathogenic variations in BRCA1 and BRCA2 have also been detected in about 65%-85% of hereditary OC as its most common cause (5). Based on these data, the study screened the BRCA1 and BRCA2 genes for pathogenic variations as a first step. Pathogenic BRCA1 and BRCA2 variations are known to be related with HBOCS and were detected in a total of 11 cases, with pathogenic BRCA1 variations being detected in 10 (90.9%) cases diagnosed as HBOCS. Only one case saw a pathogenic BRCA2 variation (c.6405_6409del; p. Asn2135Lysfs*3) was detected in only one case. The 1:10 ratio for BRCA2:BRCA1 variations is an unexpected result, as variations have been reported as being one and a half to two times higher in BRCA1 than in BRCA2 with regard to ovarian cancer (5). The ratio in this study could not be explained through the ancestry of the population as a previous study (12) of 102 Turkish ovarian cancer patients contrarily detected this ratio to be 7:10. Although their study group had a predominance of non-familial cases, which is slightly different from the current study and its predominance of familial cases, the current study’s data are not supportive enough to compare the penetrance of BRCA genes for ovarian cancer, as performing a segregation analysis was not possible here. However, another study (13) from Turkiye involved 44 ovarian cancer patients, similar to the current study, and detected pathogenic BRCA1 variations in 18 of the cases, while detecting only one patient with a BRCA2 variation. The pathogenic variation detection rate of sequencing of whole exons and the deletion duplication analysis for BRCA1 and BRCA2 genes are known to respectively be around 90% and 10% in BRCA-related HBOCS. Maistro et al. (14) reported BRCA1 rearrangements in two out of 100 OC cases, while Zhang et al.’s study (15) on 1,342 OC patients reported a gross deletion rate of 3.9% for all detected pathogenic variations in 0.5% of the cohort. This study detected CNVs in four out of 11 (36%) cases, all of which affected at least one exon of the BRCA1 gene and corresponding to 6.3% of all the OC cases. This study speculates that the approximately 10x higher rate of gross deletion duplications may be due to the small number of patients included in the study. However, the largest cohort study screening large BRCA1 rearrangements among a Turkish population including 667 OC patients detected 27 large genomic rearrangements, which corresponded to 4% of the cohort and 78% of the BRCA1 pathogenic variation carriers (16). Because of the insufficient information regarding a methodology for SNV screening, the SNV detection rates from these two studies cannot be compared. However, these two studies do indicate a higher CNV detection rate in Turkish OC patients. Yazici et al.’s study (17) also reported a BRCA1 rearrangement rate of 4% in ovarian cancer cases, which supports the previous statement.

Among the 52 non-BRCA cases, this study detected pathogenic variations in the BRIP1 and RAD50 genes of two cases. BRIP1 encodes the BRCA1-associated C-terminal helicase 1 and is one of the most commonly affected genes in non-BRCA OC patients, with approximately one-third of OC patients carrying a pathogenic variation in their BRIP1 gene (18). The BRIP1 c.139C>G (p.Pro47Ala) variation was reported previously and shown to result in complete loss of helicase activity (19). The case in the current study carrying the BRIP1 c.139C>G (p.Pro47Ala) variant had been diagnosed at the age of 55 and had first- and second-degree relatives with breast and ovarian cancer. The study detected a novel variation in the RAD50 gene (c.2083C>T; p.Gln695*) in one case, and this is predicted as being a likely pathogenic variation related to the ACMG criteria. The patient in this case was one of the youngest in the study’s cohort, with a diagnosis age of 28. Her aunt (father’s sister) was the only other known cancer case in her family, with the aunt having been diagnosed with skin cancer and dying at the age of 60. The RAD50 gene is a relatively rare one to be affected in OC patients, with Minion et al. reporting a 3% incidence rate of non-BRCA in OC cases (17). The RAD50 gene encodes an essential protein that plays an important role in repairing DNA double-strand breaks, with biallelic variations being related to a Nijmegen breakage syndrome-like disorder (OMIM: #613078) that presents itself with dysmorphic features, growth retardation, and developmental delay (20).

BRCA2 and BRIP1 biallelic variations have been related to Fanconi anemia (21), with patients possessing monoallelic variations in the BRCA2 and BRIP1 genes having been evaluated with the related autosomal recessive disorders and no such history being reported in the families. However, segregation analysis and genetic counseling were planned for at risk family members.

CONCLUSION

This study has evaluated 63 OC cases for underlying molecular deficiencies and detected the BRCA1 gene as the most commonly affected gene in OC cases, with the BRCA2, BRIP1, and RAD50 genes being the other ones in which germline cancer-related variations were detected. The high rate of CNVs in BRCA1 indicates the sequencing of cancer predisposition genes to be insufficient for OC cases and the CNV analysis of genes (especially BRCA1) should be done as the second step in molecular analysis following the BRCA1 sequencing. However, the widespread use of multigene panel tests and improvement of the CNV analysis algorithms in sequence analysis tools would help accelerate diagnostic processes. Additionally, countries with high consanguineous marriage rates such as Turkiye will benefit by informing the families of patients to be aware that preconception and/or prenatal diagnostic opportunities through genetic counseling are very important with regard to these autosomal recessive conditions and that a family-oriented approach is a required.

Ethics Committee Approval: This study was approved by the Clinical Research Ethics Committee of Marmara University Medical Faculty (24.07.2020-09.2020.751).

Informed Consent: Consent forms were taken from the patients.

Peer-review: Externally peer-reviewed.


Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol 2015; 137(1): 86-92. [CrossRef]

